INTRODUCTION

1
The cytoplasmic tyrosine kinases of the Src family (SFK) play important roles in phosphate. This lipid is likely to promote kinase activation via binding to a heterotrimeric Gi 13 protein-coupled receptor. Therefore, regulation of SFK sub-cellular localization may be an 14 important feature of signaling specificity. The molecular mechanism that governs such a 15 compartmentalization is an important issue that remains yet unexplained. 16 Cholesterol-enriched microdomains are membrane organelles with specific physical 17 features that are distinct from the contiguous membrane (26). While subjected to intense 18 debates, they are thought to function as lipid scaffolds to regulate signal transduction induced 19 by a number of extracellular stimuli including T cell receptor complexes (6, 18). Caveolae 20 define a subclass of these membrane structures in non-lymphoid cells with a diameter of 50-21 100 nm and represent the major cholesterol-enriched microdomains present in fibroblasts. 22 They are composed of caveolins, the main structural proteins, cholesterol and sphingolipids, 23 and a number of signaling molecules including growth factor receptors and SFK. Compelling 24 4 evidences indicate that they regulate signal transduction induced by growth factors and 1 integrins in non-transformed cells (19). 2 Src is subjected to strict control in non-transformed cells and constitutive kinase 3 activation leads to oncogenic properties (17). Catalytic regulation involves intramolecular 4 interactions (e.g. SH2 with the phosphorylated Tyr527 tail and the SH3 with a linker between 5 the SH2 and the catalytic core) that stabilize the kinase in a close and inactive conformation. Opening the conformation by various means is predicted to stimulate the catalytic activity. 7 Moreover, most SrcSH2 and/or SH3 binders increase Src activity in vivo and exhibit 8 mitogenic and/or transforming activity (2) . Nevertheless we and others have recently 9 identified Tom1L1 as a novel substrate and Src binder that does not induce mitogenic activity 10 while promoting kinase activity in vitro (8, 25) . This adaptor belongs to the Tom1 family of 11 proteins and presents a VHS (Vps27, Hrs and STAM) and a GAT (GGA and Tom1) 12 homology domain implicated in the regulation of vesicular trafficking (3, 16), a linker region 13 and a unique C-terminus for phosphorylation and interaction with Src. Here we show that 14 Tom1L1 interacts with Clathrin Heavy Chain (CHC) in vivo, a structural component of 15 clathrin-coated vesicles. Tom1L1, when bound to CHC, negatively regulates Src mitogenic 16 and transforming activities by reducing its level in cholesterol-enriched microdomains 17 including caveolae. Conversely, Tom1L1, when not associated with CHC, relocates in the 18 caveolae and promotes Src-driven DNA synthesis. Therefore, the Tom1L1-CHC complex 19 defines a novel mechanism for regulation of Src mitogenic and transforming activities, by 20 influencing the kinase's membrane partitioning.
21
MATERIAL AND METHODS
23
Reagents. 24 5 pBABE and pSGT constructs encoding murine Tom1L1, YFPP (Tom1L1 1 R419D/P421A/P424A/Y457F), ∆L (deletion of amino acids 292-386), ∆L/YFPP, SrcY527F, 2 PDGFRβ and Cav-3DGV were described in (8, 23, 27) . ΔC (deletion at amino acid 386 of addition. Cells were then fixed and processed for immunofluorescence as described in (9).
12
The % of transfected cells, which incorporated BrdU for each coverslips, was calculated using Cell-lysates, pull-down assays, immunoprecipitation, Western blotting, kinase assays and re-7 immunoprecipitations were performed as described in (8, 27). For biochemical analysis, cells 8 were stimulated 1 h on ice with PDGF (25 ng/ml) as described in (22). Fractionation 9 experiments were performed essentially as described in (27). Briefly, scrapped cells were 10 centrifuged and pellets suspended in 2 X-Lysis Buffer containing 1% Triton X-100, 10 mM 
RESULTS
23
CHC-Tom1L1 complex formation. 24 
8
The negative mitogenic regulation of Tom1L1 requires its C-terminus and the linker 1 regions (8). We then searched for interactors involved in this activity through an affinity-2 purification strategy coupled to mass spectrometry using HeLa cell-lysates. CHC was found 3 to be the main interactor of Tom1L1 (VS and SR, unpublished observations) and it was also 4 recently reported by Katoh et al (12) . CHC association with GST-Tom1L1 was confirmed by 5 Western blotting using CHC specific antibody (Fig. 1B) . The formation of endogenous 6 Tom1L1-CHC complex was suggested by co-immunoprecipitation of CHC with Tom1L1 in 7 NIH 3T3 cells (Fig. 1C ). The molecular mechanism by which CHC associates with Tom1L1 8 was next addressed. First, CHC exhibited in vitro affinity for the VHS, the linker and the C-9 terminus regions of Tom1L1 (Fig. 1B) . The involvement of both the Linker and the C- Leu407 were replaced by Ala barely associated with endogenous CHC when expressed in 24 HEK 293 cells (Fig. 2D) . Moreover, while GFP-Tom1L1 and CHC-DsRed exhibited a strong 9 co-localization when co-expressed in NIH 3T3 cells, (see Fig. 2E , upper panels), GFP-1 Tom1L1 ΔL/L401mutant did not co-localize with CHC-DsRed (Fig. 2E, lower panels) . We, Since Tom1L1 binds also to Src, we sought for a CHC-Tom1L1-Src ternary complex 7 formation in vitro. Purified Tom1L1 associated with bound Gst-CHC-TD at a ratio of about CHC. While no interaction was detected when only Gst-CHC-TD and Src were used in vitro, 10 an association was clearly observed in the presence of Tom1L1 (Fig. 3A) . This suggests that The CHC-Tom1L1 complex affects SFK level in caveolae. 4 We next investigated whether TomL1-CHC affects SFK sub-cellular localization in 5 caveolae. This was first addressed biochemically using caveolae-enriched fractions (CEF) (Fig. 5C ). In contrast, PDGFR activity was not affected in these 13 fractions (Fig. 5B) revealed by in vitro kinase assay of immunoprecipitated SFK from CEF (Fig. 5A, left panel) . (Fig. 5E) . Therefore, the negative effect on the mitogenic response of Tom1L1 is 4 dependent upon its association with CHC. response. The amino-terminal truncated mutant of caveolin-3, Cav-3DGV, has been described 23 to reduce both caveolae and cholesterol level from the plasma membrane (24, 27) . We have 24 also observed that this mutant blocks Src mitogenic signaling induced by PDGF (27). 
20
We next investigated the impact of CHC on Tom1L1 membrane distribution. Tom1L1 21 was barely detected in CEF when expressed in HEK 293 cells (Fig. 7A and B) . However, were deleted (Fig. 7B, right panel) . We thus concluded that Tom1L1 is mostly excluded from 4 caveolae when in association with CHC. 5 The biological significance of Tom1L1 accumulation in caveolae was next 6 investigated on Src-driven DNA synthesis (Fig. 8A) . As previously reported, wild-type Src (Fig. 8B) . We hypothesized that the capacity of mT to induce Src mitogenic activity 20 was due to its localization in cholesterol-enriched microdomains. Indeed, mT was 21 preferentially found in caveolar enriched fractions (Fig. 8C) , unlikely from Tom1L1, whose 22 membrane partitioning is regulated by CHC. We concluded that the inability of Tom1L1 to 23 induce Src mitogenic signaling was related to its exclusion from caveolae due to its 24 association with CHC. Finally, we wished to confirm the role of endogenous Src on this cellular process. We noticed that CHC depletion alone enhanced DNA synthesis from 10 to 1 15 % (Fig. 8D ). This cellular effect was abrogated by treatment of the SFK inhibitor SU6656 2 and expression of the Cav-3DGV mutant, implicating a Src mitogenic signaling regulated by 3 caveolae and/or membrane cholesterol. Similarly, we found that Tom1L1 alone also enhanced 4 DNA synthesis in cells with reduced CHC that was inhibited by the SFK inhibitor SU6656 5 ( Fig. 8D) . We concluded that Tom1L1 interacts with endogenous Src when present in 6 caveolae for DNA synthesis induction. experiments. *P < 0.05 and **P < 0.01 using a student's t-test.
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